Altimmune GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 win
Altimmune GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 win.
Altimmune is a metabolic / liver disease company. See today's news for the latest developments.
Company Info
Upcoming Milestones & Key Dates
Initial profile created
Clinical Development Pipeline
Recent News
Altimmune GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 win.
Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study.
Altimmune's GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial
Leadership Team
Leadership team
Careers & Job Openings